Cerebrolysin

Cerebrolysin is a neuropeptide preparation made by controlled enzymatic hydrolysis of porcine brain proteins — roughly 25% low-molecular-weight peptide fragments (below ~10 kDa) and 75% free amino acids. It is not a single molecule but a defined mixture, and its peptide fraction is thought to mimic endogenous neurotrophic factors. It is approved for stroke, traumatic brain injury, and dementia in many European and Asian countries (marketed by EVER Neuro Pharma), but is not FDA-approved and is treated as investigational in the US.

What is Cerebrolysin and how does it work?

Cerebrolysin's low-molecular-weight peptides can cross the blood-brain barrier and are reported to mimic or stimulate neurotrophic factors — upregulating BDNF, NGF, IGF-1, and VEGF and engaging Trk-receptor signaling (MAPK/ERK, PI3K/Akt) — which supports neuronal survival, neuroplasticity, and neurogenesis. Because it is a mixture, its activity is attributed to the peptide fraction as a whole rather than one active compound.

What does the clinical evidence actually show?

This is where honesty matters: Cerebrolysin is far better studied than a typical research peptide — it has real randomized controlled trials and Cochrane systematic reviews — …but the independent verdict is mixed, ranging from no convincing benefit in stroke to suggestive-but-not-definitive in dementia. The 2023 Cochrane review of Cerebrolysin for acute ischaemic stroke concluded it probably has no beneficial effect on death and probably increases non-fatal serious adverse events (moderate-certainty evidence), and noted that several of the trials were run with involvement of the manufacturer. Some meta-analyses report benefit (e.g. cognitive improvement in dementia at four weeks; reduced mortality/disability in severely affected stroke patients), but the highest-quality reviews counsel caution.

Source: Cerebrolysin for acute ischaemic stroke, Ziganshina L.E., Abakumova T., et al. (optional, non-blocking: complete list), Cochrane Database of Systematic Reviews, 2023 · Evidence level: approved in many countries + RCTs, but independent evidence quality is low/mixed

What are the safety and regulatory considerations?

Cerebrolysin has a long clinical track record and an established tolerability profile in its approved markets, but it is not FDA-approved, and material sold through research-chemical channels is not the approved pharmaceutical. See the legal status guide.

Why does vendor verification matter, and how does Peptigrity verify?

Because Cerebrolysin is a biologically-sourced mixture rather than a defined molecule, it can't be verified by a single expected mass — purity, composition, and absence of contaminants (via HPLC and appropriate methods) are the relevant checks, and provenance matters for an animal-derived product. Peptigrity collects independent third-party Certificates of Analysis for Cerebrolysin from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. See how to read lab results.

Educational information only; not medical advice. Cerebrolysin is not FDA-approved. Consult a qualified healthcare provider. Peptigrity does not sell, endorse, or recommend products or vendors.

Frequently asked questions